Optimizing Antiretroviral Therapy for Children Living with HIV: Experience from an Observational Cohort in Lesotho

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2023 Jul 17

PMID 37459349

Authors

Vincent J Tukei

Nicole Herrera

Matseliso Masitha

Lieketseng Masenyetse

Majoalane Mokone

Mafusi Mokone

Limpho Maile

Michelle M Gill

Affiliations

Soon will be listed here.

Abstract

Introduction: We describe transition of HIV-positive children from efavirenz- or nevirapine-based antiretroviral therapy (ART) to optimal dolutegravir (DTG) or lopinavir/ritonavir (LPV/r) (solid formulation)-based ART in Lesotho.

Methods: We followed a cohort of children less than 15 years of age who were initiated on ART on or after January 1, 2018 from 21 selected health facilities in Lesotho. From March 2020 to May 2022, we collected data retrospectively through chart abstraction and prospectively through caregiver interviews to cover a period of 24 months following treatment initiation. We used a structured questionnaire to collect data on demographics, ART regimen, drug formulations and switches, viral suppression, retention, and drug administration challenges. Data were summarized as frequencies and percentages, using SAS ver.9.4.

Results: Of 310 children enrolled in the study, 169 (54.5%) were female, and median age at ART initiation was 5.9 years (IQR 1.1-11.1). During follow-up, 19 (6.1%) children died, 41 (13.2%) were lost to follow-up and 74 (23.9%) transferred to non-study sites. At baseline, 144 (46.4%) children were receiving efavirenz-based ART regimen, 133 (42.9%) LPV/r, 27 (8.7%) DTG, 5 (1.6%) nevirapine; 1 child had incomplete records. By study end, 143 (46.1%) children were receiving LPV/r-based ART regimen, 109 (35.2%) DTG, and 58 (18.7%) were on efavirenz or nevirapine-based regimen. Of 116 children with viral load results after six months or more on a consistent regimen, viral suppression was seen in 35/53 (66.0%) children on LPV/r, 36/38 (94.7%) children on DTG and 19/24 (79.2%) children on efavirenz.

Conclusion: Following optimal ART introduction in Lesotho, most children in the cohort were transitioned and many attained or maintained viral suppression after transition; however, we recommend more robust viral load monitoring and patient tracking to reduce losses and improve outcomes after ART transition.

References

Kekitiinwa A, Musiime V, Thomason M, Mirembe G, Lallemant M, Nakalanzi S . Acceptability of lopinavir/r pellets (minitabs), tablets and syrups in HIV-infected children. Antivir Ther. 2016; 21(7):579-585. PMC: 6029664. DOI: 10.3851/IMP3054. View

Kanthula R, Rossouw T, Feucht U, van Dyk G, Beck I, Silverman R . Persistence of HIV drug resistance among South African children given nevirapine to prevent mother-to-child-transmission. AIDS. 2017; 31(8):1143-1148. PMC: 5884446. DOI: 10.1097/QAD.0000000000001446. View

Bengtson A, Espinosa Dice A, Kirwa K, Cornell M, Colvin C, Lurie M . Patient Transfers and Their Impact on Gaps in Clinical Care: Differences by Gender in a Large Cohort of Adults Living with HIV on Antiretroviral Therapy in South Africa. AIDS Behav. 2021; 25(10):3337-3346. PMC: 8840810. DOI: 10.1007/s10461-021-03191-2. View

Jean Louis F, Segaren N, Desinor O, Beard R, Jean-Louis R, Chang J . High Levels of HIV-1 Drug Resistance in Children Who Acquired HIV Infection Through Mother to Child Transmission in the Era of Option B+, Haiti, 2013 to 2014. Pediatr Infect Dis J. 2019; 38(5):503-507. PMC: 6785839. DOI: 10.1097/INF.0000000000002270. View

Jordan M, Bikinesi L, Ashipala L, Mutenda N, Brantuo M, Hunt G . Pretreatment Human Immunodeficiency Virus (HIV) Drug Resistance Among Treatment-Naive Infants Newly Diagnosed With HIV in 2016 in Namibia: Results of a Nationally Representative Study. Open Forum Infect Dis. 2022; 9(5):ofac102. PMC: 9007920. DOI: 10.1093/ofid/ofac102. View

Zurcher K, Mooser A, Anderegg N, Tymejczyk O, Couvillon M, Nash D . Outcomes of HIV-positive patients lost to follow-up in African treatment programmes. Trop Med Int Health. 2017; 22(4):375-387. PMC: 5580236. DOI: 10.1111/tmi.12843. View

Schramm B, Temfack E, Descamps D, Nicholas S, Peytavin G, Bitilinyu-Bangoh J . Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study. Lancet HIV. 2022; 9(8):e544-e553. DOI: 10.1016/S2352-3018(22)00136-9. View

Malati C, Golin R, OBrien L, Sugandhi N, Srivastava M, Larson C . Pursuing use of optimal formulations for paediatric HIV epidemic control - a look at the use of LPV/r oral pellets and oral granules. J Int AIDS Soc. 2019; 22(4):e25267. PMC: 6462808. DOI: 10.1002/jia2.25267. View

Pasipanodya B, Kuwengwa R, Prust M, Stewart B, Chakanyuka C, Murimwa T . Assessing the adoption of lopinavir/ritonavir oral pellets for HIV-positive children in Zimbabwe. J Int AIDS Soc. 2018; 21(12):e25214. PMC: 6293134. DOI: 10.1002/jia2.25214. View

10.

. Abstract Supplement Abstracts from AIDS 2022, the 24th International AIDS Conference, 29 July - 2 August 2022, Montreal, Canada & Virtual. J Int AIDS Soc. 2022; 25 Suppl 3:e25935. PMC: 9344833. DOI: 10.1002/jia2.25935. View

11.

Muri L, Gamell A, Ntamatungiro A, Glass T, Luwanda L, Battegay M . Development of HIV drug resistance and therapeutic failure in children and adolescents in rural Tanzania: an emerging public health concern. AIDS. 2016; 31(1):61-70. PMC: 5131685. DOI: 10.1097/QAD.0000000000001273. View

12.

Barlow-Mosha L, Angelidou K, Lindsey J, Archary M, Cotton M, Dittmer S . Nevirapine- Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in HIV-Infected Infants and Young Children: Long-term Follow-up of the IMPAACT P1060 Randomized Trial. Clin Infect Dis. 2016; 63(8):1113-1121. PMC: 5036919. DOI: 10.1093/cid/ciw488. View

13.

Di Carlo D, Falasca F, Palermo E, Mezzaroma I, Fimiani C, Siccardi G . Dolutegravir-Based Regimen for Maintenance of Viral Suppression in People Living with HIV: 48-Week Results in Real-Life Setting. AIDS Res Hum Retroviruses. 2021; 37(6):478-485. DOI: 10.1089/AID.2020.0196. View

14.

Abrams E, Woldesenbet S, Soares Silva J, Coovadia A, Black V, Technau K . Despite Access to Antiretrovirals for Prevention and Treatment, High Rates of Mortality Persist Among HIV-infected Infants and Young Children. Pediatr Infect Dis J. 2016; 36(6):595-601. PMC: 5432395. DOI: 10.1097/INF.0000000000001507. View

15.

Wensing A, Calvez V, Ceccherini-Silberstein F, Charpentier C, Gunthard H, Paredes R . 2019 update of the drug resistance mutations in HIV-1. Top Antivir Med. 2019; 27(3):111-121. PMC: 6892618. View

16.

Dow D, Schimana W, Nyombi B, Mmbaga B, Shayo A, Bartlett J . HIV Resistance and Prevention of Mother-to-Child Transmission Regimen in HIV-Infected Infants in Northern Tanzania. AIDS Res Hum Retroviruses. 2017; 33(11):1107-1113. PMC: 5665493. DOI: 10.1089/AID.2017.0025. View

17.

Violari A, Lindsey J, Hughes M, Mujuru H, Barlow-Mosha L, Kamthunzi P . Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med. 2012; 366(25):2380-9. PMC: 3443859. DOI: 10.1056/NEJMoa1113249. View

18.

Penazzato M, Townsend C, Rakhmanina N, Cheng Y, Archary M, Cressey T . Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list. Lancet HIV. 2019; 6(9):e623-e631. DOI: 10.1016/S2352-3018(19)30193-6. View

19.

Poppe L, Chunda-Liyoka C, Kwon E, Gondwe C, West J, Kankasa C . HIV drug resistance in infants increases with changing prevention of mother-to-child transmission regimens. AIDS. 2017; 31(13):1885-1889. PMC: 5567858. DOI: 10.1097/QAD.0000000000001569. View

20.

Nahirya-Ntege P, Cook A, Vhembo T, Opilo W, Namuddu R, Katuramu R . Young HIV-infected children and their adult caregivers prefer tablets to syrup antiretroviral medications in Africa. PLoS One. 2012; 7(5):e36186. PMC: 3342167. DOI: 10.1371/journal.pone.0036186. View